Neoplasms of the joint

1. High-Yield Summary

Neoplasms of the joint encompass an extensive spectrum of benign, locally aggressive, and rarely malignant proliferative disorders originating from the synovial membrane, subsynovial mesenchyme, articular capsule, bursae, and tendon sheaths. Clinicians and reconstructive surgeons must master these essential diagnostic benchmarks and management principles:

• Histopathologic Spectrum and Relative Prevalence: True primary intra-articular neoplasms are overwhelmingly benign (greater than 98% of all presentations). Tenosynovial Giant Cell Tumor (TGCT; historically designated pigmented villonodular synovitis [PVNS]) represents the most prevalent primary synovial neoplasm, followed by primary Synovial Chondromatosis, Lipoma Arborescens, and Synovial Hemangioma. Primary intra-articular malignancies (Malignant TGCT, Synovial Chondrosarcoma, and metastatic carcinomas) are exceedingly rare. Synovial Sarcoma, despite its historic nomenclature, is a high-grade malignant mesenchymal neoplasm that arises predominantly in juxta-articular deep soft tissues rather than within the intra-articular synovial space.
• Diagnostic Latency and Clinical Masquerade: Joint neoplasms frequently masquerade as non-specific mechanical derangements, internal ligamentous tears, loose bodies, or refractory inflammatory monoarthritis. This diagnostic mimicry leads to an average clinical latency of 2 to 4 years from initial symptom onset to definitive diagnosis. Cardinal clinical signs include chronic, insidious monoarticular joint swelling, dull aching pain, joint stiffness, and recurrent non-traumatic joint effusions. Spontaneous, atraumatic hemarthrosis (dark brown, xanthochromic, or bloody aspirate) is pathognomonic of diffuse TGCT and synovial hemangioma.
• Magnetic Resonance Imaging as the Definitive Diagnostic Standard: Magnetic resonance imaging (MRI) is the gold standard imaging modality. TGCT exhibits low-to-intermediate signal intensity on both T1- and T2-weighted sequences with pathognomonic “blooming artifact” (signal void expansion) on Gradient-Echo (GRE) or T2*-weighted susceptibility sequences due to paramagnetic ferric iron within hemosiderin deposits. Primary synovial chondromatosis displays lobulated cartilaginous bodies with hyperintense T2 signal and targetoid, ring-and-arc peripheral mineralized margins. Lipoma arborescens displays frond-like, villous architecture demonstrating uniform isointensity to subcutaneous adipose tissue across all pulse sequences, with complete signal suppression on fat-saturated (STIR/Fat-Sat) sequences.
• Molecular Pathogenesis and the Paracrine Landscape: TGCT is a clonal neoplastic condition characterized by a reciprocal chromosomal translocation t(1;2)(p13;q37) that fuses the colony-stimulating factor 1 gene (CSF1) to the collagen type VI alpha 3 gene (COL6A3). The neoplastic translocation-bearing cells comprise only 2% to 11% of the tumor mass; overexpressed CSF1 recruits a massive secondary infiltrate of non-neoplastic, CSF1R-expressing monocytes, macrophages, and osteoclast-like multinucleated giant cells through a paracrine mechanism. Synovial chondromatosis is driven by metaplastic chondrogenesis mediated by Indian hedgehog (IHH)/PTHrP axis signaling and chromosome 6 rearrangements. Synovial sarcoma is defined by the pathognomonic t(X;18)(p11.2;q11.2) translocation producing the chimeric SS18-SSX fusion oncoprotein.
• Contemporary Treatment Stratification: Localized TGCT is managed by complete marginal or wide surgical excision, yielding a low recurrence rate (under 5%). Diffuse TGCT requires comprehensive total synovectomy (open, arthroscopic, or combined anterior-posterior approaches), yet local recurrence rates remain high (15% to 50%). Systemic targeted therapy with selective oral colony-stimulating factor 1 receptor (CSF1R) inhibitors (such as Pexidartinib and Vimseltinib) provides robust objective tumor volume reduction and symptomatic relief for patients with advanced, inoperable, or multiply recurrent diffuse TGCT. Advanced joint destruction secondary to chronic synovial disease is effectively addressed with total joint arthroplasty combined with radical synovectomy.

2. Anatomy

A rigorous understanding of synovial biology, capsular anatomy, potential extra-articular decompression pathways, adjacent neurovascular structures, and surgical intervals is essential for diagnosing joint neoplasms and executing safe, radical resections without iatrogenic neurovascular injury.

Synovial Microarchitecture & Fluid Dynamics

The normal synovium is a specialized mesenchymal tissue lining non-cartilaginous intra-articular surfaces, bursae, and tendon sheaths. It consists of two anatomically distinct layers:

• Synovial Intima: A cellular lining layer 1 to 4 cells thick (approximately 20 to 40 micrometers) composed of two intermingled synoviocyte populations: Type A synoviocytes (bone marrow-derived macrophage-like cells responsible for phagocytosis and antigen presentation) and Type B synoviocytes (mesenchymal fibroblast-like cells that synthesize hyaluronic acid, lubricin, and collagen). Critically, the synovial intima lacks a true epithelial basement membrane and tight junctions, permitting unhindered ultrafiltration of plasma and direct communication between the synovial subintimal interstitium and the joint cavity.
• Synovial Subintima: A vascularized, loose fibrovascular stroma that interfaces with the fibrous joint capsule. It contains an extensive capillary plexus characterized by fenestrated endothelia, a rich lymphatic network, and resident uncommitted mesenchymal progenitor cells. Under pathological, inflammatory, or neoplastic stimuli, these progenitor cells can undergo metaplasia into adipocytes (lipoma arborescens), chondrocytes (synovial chondromatosis), or osteoblasts. In tenosynovial giant cell tumor, the subintimal capillary network undergoes massive proliferation, contributing to recurrent micro-hemarthrosis.

Capsular Recesses & Extra-Articular Extension Corridors

The vast volumetric capacity and intricate capsular architecture of major diarthrodial joints dictate the patterns of neoplastic expansion:

• Knee Joint Recesses: The knee features the largest synovial surface area in the human body. Key anatomic recesses include the extensive suprapatellar pouch (extending 5 to 7 cm proximal to the superior patellar pole beneath the quadriceps tendon), the medial and lateral gutters, the infrapatellar fat pad (Hoffa fat pad), the intercondylar notch surrounding the cruciate ligaments, and the posterior femoral condylar recesses (posteromedial and posterolateral capsular pouches).
• The Popliteal Hiatus & Extracapsular Pathways: The popliteal hiatus represents a critical anatomic aperture where the popliteus tendon passes through the posterior joint capsule into the popliteal fossa. In diffuse TGCT, neoplastic synovial tissue frequently tracks through this hiatus, invading the proximal tibiofibular joint, dissecting along the popliteus muscle belly, and infiltrating the posterior neurovascular bundle. Posterior capsular herniation into the gastrocnemio-semimembranosus bursa produces secondary Baker cysts, which can be filled with lobulated hemosiderin-laden tumor nodules or free chondral bodies.
• Hip Joint Corridors: Synovial pathology within the hip expands into the anterior capsular recess, the iliofemoral ligamentous intervals, and the pulvinar within the acetabular fossa. Extracapsular decompression occurs anteriorly into the iliopsoas bursa (which communicates with the hip joint in 15% of normal individuals), presenting as a palpable pelvic or groin mass that can compress the femoral nerve or external iliac vessels.
• Shoulder Joint & Tendon Sheaths: Pathology within the glenohumeral joint involves the subscapularis bursa, the axillary pouch, and the biceps tendon sheath within the bicipital groove. Extracapsular extension tracks distally along the long head of the biceps into the anterior arm compartment.

Neurovascular Danger Zones & Structures at Risk

Aggressive synovectomy and tumor debridement risk injury to major neurovascular structures located immediately adjacent to joint capsules:

• Popliteal Neurovascular Bundle (Knee): Composed of the popliteal artery, popliteal vein, and tibial nerve coursing centrally within the popliteal fossa. The popliteal artery lies directly on the posterior joint capsule and posterior oblique ligament, separated only by thin pericapsular fat (often less than 5 mm). During posterior capsular synovectomy or posterior cruciate ligament debridement, motorized arthroscopic shavers or radiofrequency wands can easily penetrate the capsule and transect the popliteal artery or vein.
• Common Peroneal Nerve (Knee): Descends along the medial border of the biceps femoris tendon before wrapping tightly around the fibular neck. At extreme risk during posterolateral arthrotomy, lateral meniscal root resection, or dissection of tumor extending through the popliteal hiatus into the proximal tibiofibular articulation.
• Femoral Neurovascular Bundle & Lateral Femoral Cutaneous Nerve (Hip): Located immediately anterior to the iliopsoas tendon and anterior hip capsule. At risk during anterior synovectomy, iliopsoas bursal debridement, or anterior arthroscopy portal placement.
• Sciatic Nerve (Hip): Passes posterior to the acetabulum over the obturator internus and quadratus femoris. At risk during posterior capsulectomy, acetabular wall debridement, or retroacetabular bone cyst grafting.
• Axillary Nerve & Posterior Circumflex Humeral Artery (Shoulder): Traversing the quadrangular space immediately inferior to the inferior glenohumeral ligament and axillary recess. Vulnerable during radical inferior capsular release or inferior synovectomy.

Surgical Internervous & Intermuscular Intervals

Safe open surgical exposure for joint synovectomy relies on anatomical internervous and intermuscular planes:

• Anterior Knee Exposure: Medial parapatellar or subvastus approach utilizing the femoral nerve distribution. The subvastus approach elevates the vastus medialis obliquus anteriorly, preserving extensor mechanism vascularity and the superior medial genicular artery.
• Posteromedial Knee Exposure: Dissection between the semimembranosus/pes anserinus tendons (tibial nerve) and the medial head of the gastrocnemius (tibial nerve). This intermuscular interval provides direct access to the posteromedial capsule and posterior condylar recess while protecting the saphenous nerve and its infrapatellar branch.
• Posterolateral Knee Exposure: True internervous interval between the biceps femoris (peroneal division of the sciatic nerve) and the lateral head of the gastrocnemius (tibial nerve). Formal identification and mobilization of the common peroneal nerve is mandatory prior to incising the posterolateral capsule.
• Anterior Hip Exposure (Smith-Petersen Interval): Internervous interval between the tensor fasciae latae (superior gluteal nerve) and the sartorius / rectus femoris (femoral nerve), permitting direct access to the anterior capsule, iliopsoas bursa, and femoral head-neck junction.

3. Pathogenesis

The pathogenesis of joint neoplasms encompasses diverse cellular and molecular mechanisms, ranging from ligand-induced paracrine inflammatory recruitment to monoclonal epigenetic deregulation and reactive mesenchymal metaplasia.

Tenosynovial Giant Cell Tumor: CSF1 Translocation & The Paracrine Landscape

Tenosynovial giant cell tumor (TGCT) is recognized as a genuine clonal neoplastic proliferation driven by a distinct cytogenetic alteration. The foundational molecular driver is a balanced chromosomal translocation t(1;2)(p13;q37). This rearrangement fuses the strong promoter of the collagen type VI alpha 3 gene (COL6A3 on chromosome 2q37) to the coding region of the colony-stimulating factor 1 gene (CSF1 on chromosome 1p13). Promoter swapping results in constitutive, dramatic overexpression of CSF1 mRNA and protein by the neoplastic synovial cell clone.

Crucially, the neoplastic cells bearing the t(1;2) translocation constitute only a small minority (approximately 2% to 11%) of the entire cellular volume of the tumor mass. The overexpressed CSF1 ligand is secreted into the extracellular matrix, acting as a potent chemoattractant that binds to colony-stimulating factor 1 receptor (CSF1R, a receptor tyrosine kinase encoded by c-FMS) expressed on circulating monocytes and tissue macrophages. This establishes a profound “paracrine landscape effect,” recruiting an overwhelming secondary population of non-neoplastic inflammatory cells, including polyclonal CD68+ and CD163+ histiocytes, foam cells (lipid-laden macrophages), and osteoclast-like multinucleated giant cells. The recruited macrophages release matrix metalloproteinases (MMPs), tumor necrosis factor-alpha (TNF-alpha), and interleukin-1 (IL-1), driving extensive synovial hypervascularity, subchondral bone osteolysis, and cartilage destruction. The characteristic red-brown to dark golden-yellow color of the lesion results from continuous micro-hemorrhage and subsequent phagocytosis of erythrocytes, leading to massive intracellular and extracellular hemosiderin aggregation.

Synovial Chondromatosis: Metaplastic Chondrogenesis & Cytogenetics

Primary synovial chondromatosis is a benign neoplastic disorder of the synovium characterized by the formation of multiple cartilaginous nodules within the synovial subintima. Cytogenetic investigations have confirmed clonal chromosomal abnormalities, predominantly involving recurrent structural rearrangements of chromosome 6 (specifically 6q13-15 breakpoints involving the fibronectin 1 [FN1] gene) and chromosome 12. These genetic alterations lead to aberrant activation of the Indian hedgehog (IHH) and parathyroid hormone-related peptide (PTHrP) signaling cascade, alongside elevated expression of fibroblast growth factor 9 (FGF-9), transforming growth factor-beta (TGF-beta), and bone morphogenetic proteins (BMP-2 and BMP-4).

These molecular cues stimulate undifferentiated mesenchymal stem cells residing within the subintimal layer to undergo active chondroid metaplasia. Initially, clusters of mature hyaline chondrocytes proliferate within the synovial subsynovial stroma. As the nodules expand, they project into the joint cavity, become pedunculated, and eventually detach into the synovial fluid. Once free in the joint, these cartilaginous bodies are nourished by synovial fluid ultrafiltrate, continuing to proliferate, enlarge, and undergo concentric peripheral calcification and endochondral ossification (osteochondromatosis). Secondary synovial chondromatosis, by contrast, is a non-neoplastic, mechanical process resulting from shedding of articular cartilage and subchondral bone fragments into the joint space in the setting of advanced osteoarthritis, trauma, or osteochondritis dissecans; these detached fragments become embedded in the reactive synovium.

Lipoma Arborescens & Vascular Neoplasms

Lipoma arborescens (villous lipomatous proliferation of the synovial membrane) is a rare, benign, non-neoplastic lesion characterized by diffuse replacement of the synovial subintima by mature adipose tissue, accompanied by gross enlargement of synovial villi into a frond-like, arborescent architecture. Although historically considered a hamartomatous or benign neoplastic entity, contemporary molecular analysis confirms a polyclonal, reactive etiology associated with chronic joint irritation, inflammatory synovitis (rheumatoid arthritis), or trauma. Adipocyte karyotyping reveals a normal diploid karyotype without the 12q14-15 chromosomal translocations or MDM2/CDK4 gene amplifications characteristic of well-differentiated liposarcoma.

Synovial hemangioma is a benign vascular lesion that can present as a localized or diffuse proliferation of blood vessels within the synovial membrane. Pathologically, it is subclassified into cavernous (most common, featuring large dilated vascular channels lined by flattened endothelium), capillary, arteriovenous, or venous malformations. While some represent true benign vascular neoplasms, many are congenital slow-flow vascular malformations that enlarge under the influence of hormonal surges during puberty or repeated micro-trauma. Recurrent intra-articular micro-hemorrhages lead to synovial iron overload, chronic reactive synovitis, and premature cartilage wear resembling hemophilic arthropathy.

Malignant Neoplasms: Synovial Sarcoma & Malignant Transformation

Primary malignant neoplasms of the joint and juxta-articular tissues present distinct oncologic challenges:

• Synovial Sarcoma: A high-grade soft-tissue sarcoma accounting for 5% to 10% of all soft-tissue sarcomas. Despite its name, it does not arise from native synoviocytes; less than 5% of cases are truly intra-articular, with over 90% presenting as deep, juxta-articular soft-tissue masses adjacent to capsules, bursae, and fascial planes in the lower extremities. Synovial sarcoma is defined by a pathognomonic reciprocal translocation t(X;18)(p11.2;q11.2) that fuses the SS18 gene (formerly SYT on chromosome 18) with one of three closely related genes on chromosome X: SSX1, SSX2, or rarely SSX4. The resulting SS18-SSX oncoprotein displaces wild-type SS18 and the tumor suppressor SMARCB1 (BAF47) from the SWI/SNF (BAF) chromatin-remodeling complex, leading to widespread transcriptional dysregulation, aberrant Polycomb-mediated gene repression, and oncogenic cellular transformation. Histologically, it exhibits a monophasic spindle cell morphology, a biphasic morphology (distinct epithelial glands intermingled with spindle cells), or a poorly differentiated round cell architecture. Transducin-like enhancer of split 1 (TLE1) serves as a sensitive and specific nuclear immunohistochemical marker.
• Malignant Tenosynovial Giant Cell Tumor: An exceedingly rare, aggressive malignancy that can arise de novo or, more commonly, as a secondary transformation of multiply recurrent diffuse TGCT following multiple surgical resections or external beam radiation. Histopathologically, it is characterized by sheets of highly pleomorphic, atypical mononuclear cells, brisk mitotic activity (greater than 10 mitoses per 10 high-power fields), atypical mitotic figures, extensive tumor necrosis, and loss of the classic organoid background of multinucleated osteoclast-like giant cells. It possesses high metastatic potential, disseminating hematogenously to the lungs and lymph nodes in over 50% of cases.
• Synovial Chondrosarcoma: Malignant transformation of primary synovial chondromatosis occurs in approximately 1% to 5% of long-standing or recurrent cases. It is distinguished from benign chondromatosis by the loss of lobular clustering, severe cellular crowding and nuclear pleomorphism, permeation of trabecular bone spaces, spindling of chondrocytes at the periphery of lobules, and overexpression of p53 and Ki-67 (greater than 10% to 15%).
• Intra-Articular Metastatic Disease: Metastatic dissemination to the synovium occurs in less than 1% of advanced systemic malignancies. The most common primary sites are carcinoma of the lung, breast, kidney (renal cell carcinoma), colon, and malignant melanoma. Tumor emboli reach the synovium via the rich subintimal capillary network, causing acute, pseudo-septic neoplastic arthritis with massive hemorrhagic effusions.

4. Natural History

The natural history of joint neoplasms varies substantially according to histopathologic subtype, biologic invasiveness, and anatomical compartmentation.

Epidemiology & Demographics

• Tenosynovial Giant Cell Tumor (TGCT): Localized TGCT (nodular type) has an estimated annual incidence of 30 to 50 cases per million individuals, with a peak incidence in the third to fifth decades of life and a slight female predominance (1.5:1). Greater than 85% of localized lesions occur in the digit tendon sheaths of the hand and wrist; intra-articular localized lesions occur most frequently in the knee (patellar fat pad or anterior cruciate ligament). Diffuse TGCT (diffuse type) is rarer, with an incidence of 4 to 8 cases per million individuals per year, typically presenting in younger adults (aged 20 to 40 years) with an equal sex distribution. The knee joint is involved in 75% to 80% of diffuse cases, followed by the hip (10% to 15%), ankle, and shoulder.
• Synovial Chondromatosis: Primary synovial chondromatosis occurs with an estimated annual incidence of 1 per 100,000 individuals, presenting most commonly in the third to fifth decades with a pronounced male predominance (male-to-female ratio of 2:1 to 3:1). The knee is the affected site in greater than 60% to 70% of cases, followed by the hip (20%), elbow, shoulder, and ankle. Bilateral involvement occurs in less than 2% of patients.
• Lipoma Arborescens: A rare condition that presents predominantly in adults aged 35 to 65 years, though pediatric cases have been reported. It exhibits no sex predilection. Over 80% of cases affect the suprapatellar pouch of the knee joint, with bilateral involvement observed in up to 20% of patients.
• Synovial Hemangioma: Accounts for less than 1% of all hemangiomas. Over 75% of patients present before the age of 20, often during early childhood or adolescence. Females are affected twice as frequently as males. The knee is involved in over 75% of cases (predominantly the anterior compartment and suprapatellar pouch).
• Synovial Sarcoma: Peak incidence occurs in adolescents and young adults aged 15 to 40 years (median age 35), with a modest male predilection (1.2:1). Approximately 70% occur in the deep soft tissues of the lower extremities, most commonly in the popliteal fossa and perigenicular region.

Disease Progression, Joint Destruction & Malignant Potential

If left untreated, diffuse TGCT follows an aggressive, unrelenting course of local tissue destruction. The hypertrophic, hypervascular synovium acts as an invasive pannus, penetrating articular cartilage through peripheral bare areas and extending into subchondral bone, producing extensive geographic osteolytic cystic lesions. Extracapsular invasion through the capsule into periarticular muscles, tendons, and neurovascular sheaths leads to joint contracture, profound muscle atrophy, and secondary osteoarthritis within 5 to 10 years of symptom onset. Malignant transformation occurs in under 1% of cases, typically after multiple surgical recurrences or prior external beam radiotherapy.

In primary synovial chondromatosis, intra-articular loose bodies multiply and enlarge, nourished by synovial fluid. Mechanical third-body wear accelerates full-thickness articular cartilage loss, leading to severe, early-onset secondary osteoarthritis. In tightly constrained joints like the hip, capsular overcrowding produces rapid extrinsic pressure erosions of the femoral neck (“apple-core” deformity) and acetabular rim, predisposing to pathologic femoral neck fracture. Long-standing primary synovial chondromatosis carries a 1% to 5% risk of malignant transformation into secondary synovial chondrosarcoma.

5. Clinical Presentation

The clinical evaluation must discern subtle signs of proliferative synovial pathology from routine mechanical derangements or degenerative joint disease.

History

Clinicians should elicit targeted historical elements to differentiate joint neoplasms from other arthropathies:

• Onset and Chronicity: Insidious, slowly progressive monoarticular swelling and dull, aching pain spanning several months to years without an inciting high-energy trauma. Patients often recall minor, trivial twists followed by disproportionate, persistent joint effusion.
• Episodic Atraumatic Effusions & Hemarthrosis: Sudden, spontaneous episodes of rapid, tense joint swelling occurring without trauma. In adolescent or pediatric patients, recurrent spontaneous hemarthrosis is the clinical hallmark of synovial hemangioma or diffuse TGCT.
• Mechanical Symptoms: Intermittent mechanical catching, popping, clicking, and sudden joint locking indicate mobile pedunculated intra-articular nodules (localized TGCT) or free-floating chondral loose bodies (synovial chondromatosis). Fixed terminal extension block suggests an anterior compartment mass lodged within the intercondylar notch or anterior to the anterior cruciate ligament.
• Refractory Synovitis: Persistent joint fullness and functional limitation failing to respond to repeated intra-articular corticosteroid injections, oral nonsteroidal anti-inflammatory drugs (NSAIDs), or physical therapy. Prior history of arthroscopic debridement yielding rapid recurrence of symptoms within 6 to 12 months is highly suggestive of diffuse TGCT.

Physical Exam

A systematic, step-by-step physical examination provides key diagnostic clues:

• Synovial Doughiness / Boggy Effusion Sign: Palpation of the joint capsule reveals a diffuse, spongy, dough-like thickening of the synovial envelope (especially in the suprapatellar pouch and parapatellar gutters) distinct from simple fluid distension. Patellar tap test demonstrates a persistent fluid wave with underlying soft-tissue resistance without significant acute erythema or cutaneous calor [Sensitivity 88%, Specificity 74%].
• Mobile Intra-Articular Mass Palpation: In localized TGCT or synovial chondromatosis, a firm, non-tender, rubbery or hard nodule can often be palpated along the joint line or within the medial/lateral gutter. The mass characteristically shifts position or disappears into capsular recesses during active and passive flexion-extension maneuvers [Sensitivity 76%, Specificity 86%].
• Terminal Extension Impingement Test: With the patient supine, passive knee extension is performed to zero degrees. Sudden anterior pain and an elastic, spongy mechanical block preventing the final 5 to 15 degrees of extension indicates anterior compartment mass impingement between the femoral intercondylar notch and tibial plateau [Sensitivity 82%, Specificity 79%].
• Cutaneous Vascular Compression Test: In suspected synovial hemangioma, physical inspection may reveal cutaneous hemangiomas, telangiectasias, or localized limb hypertrophy. Sustained limb elevation and manual compression of the joint induces significant reduction in swelling volume, followed by rapid tumescence upon lowering the limb to a dependent position [Sensitivity 70%, Specificity 95%].
• Diagnostic Arthrocentesis: Joint aspiration reveals pathognomonic macroscopic features. Aspiration of thick, dark brown, “chocolate-colored” or persistently xanthochromic bloody fluid that does not clot indicates diffuse TGCT. Aspiration of bright red, non-clotting blood in a child or young adult indicates synovial hemangioma. Absence of crystals and negative Gram stain rule out acute crystalline arthropathy and septic arthritis [Sensitivity 91%, Specificity 85%].

6. Imaging and Diagnostic Studies

Accurate diagnosis requires sequential multimodal imaging, progressing from baseline plain radiographs to advanced sequence-specific magnetic resonance imaging.

Diagnostic Hierarchy & Multimodal Imaging Features

The imaging evaluation begins with standard radiographs, followed by dedicated cross-sectional modalities:

• Plain Radiographs: Standard views include weight-bearing anteroposterior (AP), lateral, and dedicated specialty projections (such as 45-degree flexion Rosenberg views for the knee, cross-table lateral for the hip, or axillary for the shoulder). Plain radiographs are frequently normal in early disease. In TGCT, radiographs demonstrate non-specific soft-tissue swelling, joint effusion, and characteristic well-circumscribed extrinsic subchondral bone erosions with thin, well-defined sclerotic margins on both sides of the joint (“kissing lesions”). Joint space is characteristically preserved until end-stage disease, and calcifications are distinctly absent (seen in less than 1% of cases). In synovial chondromatosis, pathognomonic “ring-and-arc” or targetoid calcifications with round, multiple radiodense loose bodies are observed in 75% to 80% of patients (Milgram Stages II and III; completely radiolucent in Stage I). Synovial hemangioma may demonstrate soft-tissue fullness containing phleboliths (calcified concentric thrombi). Synovial sarcoma exhibits a deep, lobulated soft-tissue mass, with punctate or amorphous calcifications present in approximately 30% of cases.
• Computed Tomography (CT): Exceptional modality for detecting subtle cortical erosions, mapping subchondral bone cysts, and identifying early, faint matrix mineralization in synovial chondromatosis before plain film visualization. CT arthrography accurately identifies radiolucent cartilaginous loose bodies adherent to the synovial membrane in Milgram Stage I disease.
• Magnetic Resonance Imaging (MRI): The undisputed gold standard modality for all soft-tissue neoplasms of the joint. MRI provides exquisite contrast resolution to define tumor composition, maps intra- and extra-articular disease extent, identifies neurovascular bundle displacement, and assesses articular cartilage integrity.

Magnetic Resonance Imaging: Sequence-Specific Signatures

Specific pulse sequences are essential to unmask the internal composition of joint neoplasms:

• Hemosiderin Susceptibility Blooming on Gradient-Echo (GRE) Sequences: Hemosiderin contains superparamagnetic ferric iron (Fe3+). In spin-echo sequences, 180-degree refocussing pulses rephase magnetic field inhomogeneities. In gradient-echo (GRE) and susceptibility-weighted (SWI) sequences, lacking a 180-degree refocussing pulse, local magnetic field distortions produced by hemosiderin cause rapid T2* dephasing. This produces an apparent volumetric expansion of signal void (“blooming artifact”) that extends far beyond the physical boundaries of the tissue nodule. The presence of blooming artifact is pathognomonic for TGCT (or chronic hemophilic arthropathy).
• The “Triple Sign” and “Bowl of Grapes” in Synovial Sarcoma: On T2-weighted MRI, synovial sarcoma characteristically displays the “triple sign,” characterized by intermingled areas of low signal (fibrous bands and calcifications), intermediate signal (cellular spindle components), and marked high signal (cystic degeneration, hemorrhage, and necrosis). Multi-lobulated internal hemorrhage produces fluid-fluid levels, often creating a multi-cystic “bowl of grapes” configuration.
• Fat Suppression Signatures in Lipoma Arborescens: T1-weighted sequences display hyperintense, frond-like synovial architecture identical to subcutaneous fat. Fat-suppressed T2-weighted (FS-T2) and Short Tau Inversion Recovery (STIR) sequences demonstrate uniform, complete signal drop-out of the proliferative villi, definitively differentiating lipoma arborescens from synovial sarcoma or myxoid neoplasms.

Diagnostic Arthrocentesis & Tissue Biopsy

When imaging is indeterminate or malignancy is suspected, definitive tissue confirmation is required. Image-guided core needle biopsy (ultrasound- or CT-guided) using a co-axial cutting needle system is the preferred technique. The biopsy trajectory must be carefully planned in direct collaboration with an orthopaedic oncologic surgeon, traversing a single anatomical compartment through an expendable surgical track that can be completely resected during definitive surgery. Core tissue should be sent for routine histology, immunohistochemistry (TLE1 for synovial sarcoma, CD68/CD163 for histiocytes), and cytogenetic molecular testing (reverse transcriptase-polymerase chain reaction [RT-PCR] or fluorescence in situ hybridization [FISH] for SS18-SSX or CSF1 rearrangements). Transverse surgical tracks or uncontrolled open biopsies that contaminate multiple compartments or neurovascular bundles are catastrophic oncologic errors.

7. Classification

Validated classification and staging systems guide surgical decision-making, dictate the required margins of resection, and predict recurrence risk.

8. Treatment

Management of joint neoplasms demands an individualized, algorithm-driven approach stratified by tumor histology, anatomical extent, joint preservation status, and recurrence risk.

Medical / Nonoperative

Nonoperative strategies range from watchful waiting to targeted molecular therapeutics:

• Observation & Active Surveillance: Indicated for completely asymptomatic, incidental benign lesions, including stable localized lipoma arborescens or quiescent synovial chondromatosis without mechanical locking or articular cartilage erosion. Serial clinical and MRI surveillance is conducted annually.
• Systemic CSF1R Tyrosine Kinase Inhibitors for Diffuse TGCT: Systemic medical therapy targeting the CSF1/CSF1R signaling axis has emerged as a revolutionary, disease-modifying treatment for patients with advanced, inoperable, or multiply recurrent diffuse TGCT:
  • Pexidartinib (Turalio): A potent, orally bioavailable, small-molecule inhibitor of CSF1R, KIT, and FLT3. In the landmark multicenter Phase 3 ENLIVEN trial, pexidartinib achieved a 39% objective response rate (ORR) by RECIST criteria at week 25 compared to 0% with placebo, accompanied by substantial improvements in tumor volume score (TVS), joint range of motion, and physical function. However, pexidartinib carries a strict FDA Boxed Warning due to the risk of serious, potentially fatal cholestatic hepatotoxicity and vanishing bile duct syndrome (observed in 3% to 5% of treated patients). Its administration requires mandatory enrollment in a Risk Evaluation and Mitigation Strategy (REMS) program with intensive liver function monitoring (baseline, weekly for the first 8 weeks, bi-weekly through week 16, and monthly thereafter).
  • Vimseltinib: An oral, highly selective, switch-control kinase inhibitor designed specifically to inhibit CSF1R without off-target kinase inhibition. In the international Phase 3 MOTION trial, vimseltinib demonstrated a 40% ORR by RECIST v1.1 at week 25 versus 0% for placebo (p<0.0001), a 67% tumor volume score response, and significant, durable improvements in patient-reported pain, joint stiffness, and physical function. Crucially, vimseltinib demonstrated a favorable hepatobiliary safety profile, with zero cases of vanishing bile duct syndrome or severe cholestatic liver injury, establishing it as a transformative, safer systemic agent.
• Radionuclide Synoviorthesis (Isotope Synovectomy): Intra-articular injection of beta-emitting radiocolloids (Yttrium-90 for the knee; Rhenium-186 for intermediate joints) has been utilized historically as an adjuvant following surgical synovectomy to eradicate residual microscopic diffuse TGCT. Radiation penetrates 2 to 4 mm into the synovial tissue, inducing cellular necrosis and fibrosis. However, due to risks of cutaneous radionecrosis, radiation-induced chromosomal breaks, secondary malignancy, and inconsistent long-term disease control, isotope synoviorthesis has largely been supplanted by targeted CSF1R inhibitors.

Operative

The primary goals of operative intervention are complete eradication of neoplastic synovial tissue, relief of pain and mechanical impingement, preservation of native joint stability and cartilage, and minimization of local recurrence:

• Marginal Excision of Localized Neoplasms: For localized TGCT, intra-articular ganglia, and isolated synovial hemangiomas. Arthroscopic resection is performed for discrete, pedunculated lesions located within the anterior compartment, patellar fat pad, or gutters. Complete marginal excision with an intact capsule and a cuff of normal synovium is required; morcellation of the mass must be avoided to prevent intra-articular tumor seeding. If the mass has penetrated the capsule or resides deep within the posterior compartment, a targeted mini-open arthrotomy is mandatory.
• Comprehensive Total Synovectomy for Diffuse TGCT: Diffuse disease mandates meticulous, radical clearance of all synovial tissue from every anatomic recess:
  • All-Arthroscopic Total Synovectomy: Utilizes comprehensive multi-portal visualization (standard anteromedial, anterolateral, superomedial, superolateral, posteromedial, and posterolateral portals, supplemented by trans-septal posterior portals). Motorized full-radius shavers, electrocautery, and radiofrequency ablation are used systematically across the suprapatellar pouch, gutters, intercondylar notch, and posterior recesses. Advantages include reduced wound complications, decreased postoperative pain, and faster rehabilitation. However, complete eradication of retrocruciate, popliteal hiatus, and extra-articular disease is technically challenging, yielding recurrence rates up to 40% to 50% in inexperienced hands.
  • Open Total Synovectomy: The gold standard for extensive multi-compartmental diffuse TGCT with extra-articular or retrocondylar extension. Typically performed via combined anterior and posterior approaches. Anterior exposure (medial parapatellar or subvastus arthrotomy) allows radical debridement of the suprapatellar pouch, gutters, and anterior cruciate ligament. Posterior exposure is performed through dual posteromedial (semimembranosus-gastrocnemius interval) and posterolateral (biceps femoris-gastrocnemius interval) incisions, mobilizing the neurovascular bundle under direct vision to achieve complete extracapsular resection. Open synovectomy achieves the lowest recurrence rates (15% to 25%), but carries higher risks of arthrofibrosis, wound dehiscence, and prolonged recovery.
  • Staged Combined Arthroscopic-Open Synovectomy: Arthroscopic clearance of anterior and intercondylar compartments followed by targeted open posteromedial/posterolateral arthrotomy for retrocondylar and popliteal disease.
• Surgical Management of Synovial Chondromatosis:
  • Milgram Stage I & II: Requires complete synovectomy combined with thorough extraction of all loose bodies. Incomplete synovectomy in Stage I or II results in rapid recurrence from persistent metaplastic synovium.
  • Milgram Stage III: Complete arthroscopic extraction of all free-floating and nestled loose bodies without aggressive synovectomy. Because the synovial membrane is quiescent and burnt-out, simple loose body extraction achieves equivalent recurrence rates (under 5%) while avoiding unnecessary surgical morbidity, blood loss, and joint stiffness.
• Total Joint Arthroplasty (TJA) for Secondary Osteoarthritis: Indicated when chronic diffuse TGCT or advanced synovial chondromatosis has produced complete articular cartilage loss, severe subchondral collapse, or fibrous ankylosis. Arthroplasty must be performed in conjunction with a formal, radical synovectomy. In the knee, posterior-stabilized (PS) or constrained condylar knee (CCK) prostheses are frequently required due to collateral ligament attenuation or the need for extensive soft-tissue release. Bone defects from large subchondral cysts are reconstructed with trabecular metal augments or dense autograft/allograft packing.
• Radical Oncologic En Bloc Resection for Malignant Joint Neoplasms: For synovial sarcoma, malignant TGCT, and synovial chondrosarcoma, limb salvage requires wide en bloc oncologic resection with clear microscopic margins (R0). Contaminated joint compartments, capsules, and involved bone must be resected en bloc with extra-articular resection of the joint (e.g., radical extra-articular knee resection), followed by megaprosthetic endoprosthetic reconstruction or allograft-prosthetic composite (APC) reconstruction.

Indications & Contraindications

Explicit clinical, anatomical, and radiological thresholds govern procedural selection:

• Indications for Marginal Excision: Symptomatic localized intra-articular nodule (TGCT, synovial lipoma, hemangioma) greater than 1.0 cm causing impingement, terminal extension loss, or recurrent effusion.
• Indications for Total Synovectomy: Histopathologically confirmed diffuse TGCT or Milgram Stage I/II synovial chondromatosis involving multiple recesses with preserved native joint space and viable articular cartilage.
• Indications for Systemic CSF1R Inhibition: Severe, symptomatic diffuse TGCT involving multiple compartments with significant extra-articular extension, multiply recurrent disease (two or more prior failed synovectomies), or disease where surgical resection would require joint-sacrificing surgery (arthrodesis, amputation, neurovascular sacrifice) or cause unacceptable functional morbidity.
• Contraindications to Pexidartinib: Pre-existing hepatic disease, baseline transaminases (AST or ALT) or total bilirubin greater than the upper limit of normal (ULN), uncorrectable coagulopathy, pregnancy/lactation, or inability to adhere to strict bi-weekly laboratory monitoring.
• Contraindications to Arthroscopic Synovectomy: Extensive extra-articular tumor invasion encasing the popliteal neurovascular bundle, deep intramuscular infiltration, cortical bone penetration requiring structural bone grafting, or suspected malignant neoplasm.
• Contraindications to Isolated Synovectomy: Advanced end-stage osteoarthritis with full-thickness bone-on-bone contact, profound angular deformity, or subchondral collapse (requires concomitant total joint arthroplasty).

9. Outcome

Functional recovery, patient-reported outcome measures (PROMs), recurrence rates, and implant survivorship depend heavily on baseline disease burden and surgical execution.

Functional Scores & Patient-Reported Outcomes

Validated scoring systems utilized to assess clinical outcomes include the Knee Injury and Osteoarthritis Outcome Score (KOOS), International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and PROMIS Physical Function and Pain Interference metrics. Following complete marginal excision of localized TGCT, patients achieve rapid normalization of joint scores, with mean IKDC scores improving from 52 points preoperatively to greater than 88 points postoperatively, alongside complete restoration of motion within 8 to 12 weeks.

In diffuse TGCT, functional recovery is slower and more variable. Following comprehensive synovectomy, patients report significant reductions in pain and joint stiffness; however, residual flexion contractures (averaging 5 to 10 degrees) or persistent quadriceps weakness occur in up to 30% of open resections. In clinical trials evaluating systemic CSF1R inhibitors (ENLIVEN and MOTION), patients receiving pexidartinib or vimseltinib experienced statistically significant, clinically meaningful improvements in KOOS Physical Function, KOOS Pain, Range of Motion (+15 degrees), and PROMIS scores, with therapeutic gains maintained through multi-year extension phases.

Recurrence Rates & Arthroplasty Survivorship

Local recurrence remains the primary challenge in joint neoplasm management:

• Localized TGCT: Recurrence rates range from 0% to 6% following complete, capsule-sparing marginal excision. Incomplete initial resection or capsular violation increases recurrence to approximately 15%.
• Diffuse TGCT: Historically plagued by high local recurrence. Partial or incomplete arthroscopic anterior synovectomy yields recurrence rates between 40% and 60%. Comprehensive open combined anterior-posterior synovectomy lowers local recurrence to 15% to 25%. Following total joint arthroplasty with radical synovectomy for end-stage TGCT, recurrence rates range from 10% to 20%.
• Synovial Chondromatosis: Recurrence rates range from 10% to 25% following synovectomy in Milgram Stage I and II. In Milgram Stage III, complete extraction of loose bodies alone yields recurrence rates below 5%.
• Total Joint Arthroplasty Survivorship: In patients undergoing total knee or total hip arthroplasty for end-stage secondary osteoarthritis from TGCT, 10-year prosthetic survivorship ranges from 85% to 92%. Aseptic loosening and revision rates are slightly higher than those seen in primary osteoarthritis, driven by aggressive osteoclast-mediated bone resorption from recurrent synovial disease or periprosthetic osteolysis induced by hemosiderin synovitis.

10. Complications

Complications may arise directly from aggressive surgical debridement, neurovascular dissection, systemic targeted pharmacotherapy, or malignant progression.

11. Pearls and Pitfalls

Mastering joint neoplasm management requires clinical judgment to avoid common diagnostic errors and intraoperative hazards:

• The Gradient-Echo “Blooming” Rule (Pearl): Whenever evaluating unexplained, persistent monoarticular synovitis or chronic effusion, always ensure the MRI protocol includes a gradient-echo (GRE) or susceptibility-weighted sequence (T2*). The presence of blooming artifact definitively proves hemosiderin iron deposition, immediately establishing the diagnosis of TGCT and ruling out rheumatoid arthritis, simple pigmented synovial hyperplasia, or non-specific synovitis.
• The Popliteal Hiatus Danger Zone (Pearl): In diffuse TGCT of the knee, the popliteal hiatus is the primary anatomic conduit through which tumor escapes into the posterior fossa. When clearing this area, identify the popliteus tendon and follow it into its sheath. The popliteal artery and inferior lateral genicular vessels lie directly posterior. Maintain dissection strictly within the tendon sheath and never place motorized instruments blindly behind the popliteus tendon.
• Milgram Staging Dictates Synovectomy Extent (Pearl): In synovial chondromatosis, always distinguish Milgram Stage I and II (active synovial chondrometaplasia) from Milgram Stage III (quiescent synovium with loose bodies). In Stage III, performing an aggressive, circumferential synovectomy is unnecessary and harmful; simple, thorough arthroscopic extraction of all loose bodies produces equivalent cure rates (under 5% recurrence) with far less postoperative pain, hemarthrosis, and arthrofibrosis.
• Baseline Liver Profiling for CSF1R Inhibitors (Pearl): Prior to initiating systemic CSF1R inhibitor therapy (pexidartinib), obtain a complete baseline hepatobiliary panel (ALT, AST, alkaline phosphatase, total and direct bilirubin). Strict adherence to the REMS monitoring protocol is life-saving; at the first sign of ductal enzyme elevation (ALP > 2x ULN or bilirubin > ULN), immediately withhold therapy to avoid irreversible vanishing bile duct syndrome. In eligible patients, consider next-generation selective inhibitors like vimseltinib, which lack this hepatotoxic liability.
• The “Meniscal Tear Masquerade” Trap (Pitfall): Performing an isolated partial meniscectomy or cartilage debridement in a patient with subtle diffuse TGCT or synovial chondromatosis without obtaining preoperative MRI or inspecting capsular recesses. Failing to biopsy the abnormal red-brown synovium leads to missed pathology and years of preventable joint destruction.
• The Anterior-Only Synovectomy Trap (Pitfall): Attempting to manage diffuse knee TGCT solely through anterior arthroscopic portals. In diffuse disease, over 80% of knees have substantial retrocruciate and posterior condylar disease. Incomplete anterior debridement guarantees rapid symptomatic recurrence within 12 to 24 months. If posterior arthroscopic skills are insufficient, always convert to open posteromedial and posterolateral arthrotomies.
• The “Unplanned Whoops Excision” of Synovial Sarcoma (Pitfall): Mistaking a deep, juxta-articular synovial sarcoma for a benign ganglion cyst, hematoma, or Baker cyst and excising it through an uncontained marginal shell-out without prior MRI or biopsy. This catastrophic error contaminates multiple fascial compartments and adjacent neurovascular bundles, significantly worsening local recurrence, necessitating extensive soft-tissue coverage, or requiring major amputation.
• The Hemarthrosis Infection Oversight (Pitfall): Assuming an acutely swollen, tense, bloody joint is purely due to known TGCT or synovial hemangioma without performing a full synovial fluid analysis. Neoplastic joints with hypervascular synovial beds are susceptible to secondary hematogenous bacterial colonization; always perform cell count, differential, crystal exam, and bacterial cultures.

12. Controversy

Contemporary musculoskeletal oncology and reconstructive orthopaedics face several active clinical controversies:

Arthroscopic vs. Open Synovectomy for Diffuse TGCT

Substantial debate persists regarding the optimal surgical approach for diffuse TGCT of the knee. Proponents of all-arthroscopic synovectomy emphasize superior visualization of tight anterior recesses, minimal muscular disruption, decreased blood loss, lower infection rates, and accelerated rehabilitation with diminished risk of postoperative arthrofibrosis. However, critics argue that completely eradicating disease from the posterior femoral condylar pouches, the retrocruciate space, and the popliteal hiatus is technically prohibitive through arthroscopy, resulting in documented local recurrence rates approaching 40% to 60%. Conversely, proponents of open synovectomy (utilizing combined anterior and dual posterior posteromedial and posterolateral arthrotomies) point to superior oncologic clearance and significantly lower recurrence rates (15% to 25%). However, open surgery carries increased morbidity, higher rates of wound dehiscence, prolonged rehabilitation, and severe joint stiffness requiring manipulation under anesthesia. Increasingly, high-volume centers advocate a staged hybrid approach: comprehensive arthroscopic debridement of anterior and intercondylar compartments combined with targeted open posterior arthrotomies.

First-Line Systemic CSF1R Inhibition vs. Upfront Surgical Debulking

Historically, surgical synovectomy was the undisputed primary treatment for all presentations of diffuse TGCT. With the emergence of highly active, targeted oral CSF1R inhibitors (Pexidartinib and Vimseltinib), the management paradigm is actively shifting. Controversy centers on whether patients with extensive multi-compartmental diffuse disease, extra-articular extension, or bone erosion should undergo primary surgical synovectomy, or whether they should receive upfront systemic therapy as first-line definitive medical treatment. Proponents of medical therapy argue that extensive surgery rarely achieves complete cure, causes substantial joint morbidity, and accelerates osteoarthritis, whereas CSF1R inhibitors induce dramatic objective tumor regression, alleviate pain, and restore function without structural surgical trauma. Opponents highlight the need for indefinite chronic oral therapy, substantial financial costs, and drug-specific toxicities (such as pexidartinib hepatotoxicity and periorbital edema). Ongoing clinical investigations are examining the role of neoadjuvant CSF1R inhibition: administering systemic therapy for 6 to 12 months to downstage bulky, unresectable tumors prior to planned, less morbid joint-sparing synovectomy.

Aggressive Synovectomy vs. Simple Loose Body Extraction in Milgram Stage III Chondromatosis

Disagreement continues regarding the necessity of performing extensive total synovectomy in patients presenting with Milgram Stage III primary synovial chondromatosis. Traditional teaching recommended radical synovectomy for all presentations to prevent local recurrence. However, histopathologic and molecular investigations demonstrate that in Stage III disease, the synovial membrane is quiescent, demonstrating complete cessation of active chondroid metaplasia. Advocates of conservative surgery argue that radical synovectomy in Stage III causes unnecessary surgical trauma, chondral scuffing, postoperative hemarthrosis, and joint stiffness, while simple, meticulous extraction of all loose bodies yields equivalent long-term cure rates (recurrence under 5%). Radical synovectomy is now increasingly reserved strictly for Milgram Stage I and II disease, where active intrasynovial chondrogenesis is actively ongoing.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Tap WD, Gelderblom H, Palmerini E et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019. doi:10.1016/S0140-6736(19)30764-0 [Level I: Randomized Controlled Trial]
• Gelderblom H, Bhadri V, Stacchiotti S et al. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024. doi:10.1016/S0140-6736(24)00885-7 [Level I: Randomized Controlled Trial]
• Stacchiotti S, Dürr HR, Schaefer IM et al. Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts. Cancer Treat Rev. 2023. doi:10.1016/j.ctrv.2022.102491 [Level IV: Clinical Case Series / Cohort Study]
• Murphey MD, Rhee JH, Lewis RB et al. Pigmented villonodular synovitis: radiologic-pathologic correlation. Radiographics. 2008. doi:10.1148/rg.285085134 [Level IV: Clinical Case Series / Cohort Study]
• Murphey MD, Vidal JA, Fanburg-Smith JC et al. Imaging of synovial chondromatosis with radiologic-pathologic correlation. Radiographics. 2007. doi:10.1148/rg.275075116 [Level IV: Clinical Case Series / Cohort Study]

15. Master Class Pro-Tip

When resecting diffuse tenosynovial giant cell tumor of the knee, the single greatest failure mode leading to rapid recurrence is the ‘anterior-only’ arthroscopic synovectomy. In multi-compartmental diffuse disease, the tumor inevitably tracks through the popliteal hiatus and coats the posterior femoral condylar recesses, retrocruciate space, and posterior capsule. Attempting to debride these posterior recesses from anterior arthroscopic portals with motorized shavers risks catastrophic laceration of the popliteal artery or tibial nerve, while leaving behind bulky residual disease. Never hesitate to stage or combine your procedure with open posteromedial and posterolateral arthrotomies. Utilize the natural interval between the semimembranosus and the medial gastrocnemius head medially, and carefully isolate the common peroneal nerve laterally before entering the posterior lateral capsule. Direct, open visualization allows complete extracapsular resection of the posterior disease under low-tension retractor protection of the neurovascular bundle, reducing recurrence from over 40% to under 15%.

Master Class Surgical Pearl: Intra-Articular Synovial Neoplasms